Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617222 | 0.92 | SLC6A9 (0.43) | SLC6A9GALR3TRPV4ALDH1A1SMN1; SMN2 | |
| SCHEMBL603824 | 0.91 | GALR3 (0.42) | SLC6A9GALR3TRPV4ALDH1A1SMN1; SMN2 | |
| SCHEMBL616556 | 0.90 | SLC6A9 (0.41) | SLC6A9SMN1; SMN2CYP19A1CARM1PRMT6 | |
| SCHEMBL616498 | 0.89 | SLC6A9 (0.41) | SLC6A9GALR3TRPV4ALDH1A1SMN1; SMN2 | |
| SCHEMBL616159 | 0.89 | SLC6A9 (0.38) | SLC6A9GALR3TRPV4ALDH1A1SMN1; SMN2 | |
| SCHEMBL615081 | 0.89 | SLC6A9 (0.47) | SLC6A9ALDH1A1 | |
| SCHEMBL614220 | 0.88 | SLC6A9 (0.44) | SLC6A9ALDH1A1HSD11B1CYP19A1CARM1 | |
| SCHEMBL616747 | 0.87 | SLC6A9 (0.57) | SLC6A9 | |
| SCHEMBL606414 | 0.85 | SLC6A9 (0.51) | SLC6A9GALR3TRPV4ALDH1A1SMN1; SMN2 | |
| SCHEMBL616251 | 0.85 | SLC6A9 (0.56) | SLC6A9GALR3TRPV4ALDH1A1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | claimed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | claimed |
| EP-2709987-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2014-03-26 | — | — | EP | claimed |
| CN-103180299-A | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO KG | 2013-06-26 | — | — | CN | claimed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | claimed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | claimed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | claimed |
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | SLC6A9 42/4885GALR3 462/4885TRPV4 748/4885 |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | SLC6A9 42/4885GALR3 462/4885TRPV4 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.